0001179110-17-014574.txt : 20171122
0001179110-17-014574.hdr.sgml : 20171122
20171122165258
ACCESSION NUMBER: 0001179110-17-014574
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171120
FILED AS OF DATE: 20171122
DATE AS OF CHANGE: 20171122
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ABERCROMBIE GEORGE B
CENTRAL INDEX KEY: 0001485939
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30319
FILM NUMBER: 171220467
MAIL ADDRESS:
STREET 1: C/O INSPIRE PHARMACEUTICALS, INC.
STREET 2: 4222 EMPEROR BLVD., SUITE 200
CITY: DURHAM
STATE: NC
ZIP: 27703
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Innoviva, Inc.
CENTRAL INDEX KEY: 0001080014
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943265960
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2000 SIERRA POINT PARKWAY
STREET 2: SUITE 500
CITY: BRISBANE
STATE: CA
ZIP: 94005
BUSINESS PHONE: 6502389600
MAIL ADDRESS:
STREET 1: 2000 SIERRA POINT PARKWAY
STREET 2: SUITE 500
CITY: BRISBANE
STATE: CA
ZIP: 94005
FORMER COMPANY:
FORMER CONFORMED NAME: THERAVANCE INC
DATE OF NAME CHANGE: 20020207
FORMER COMPANY:
FORMER CONFORMED NAME: ADVANCED MEDICINE INC
DATE OF NAME CHANGE: 20000302
4
1
edgar.xml
FORM 4 -
X0306
4
2017-11-20
0
0001080014
Innoviva, Inc.
INVA
0001485939
ABERCROMBIE GEORGE B
2000 SIERRA POINT PARKWAY
SUITE 500
BRISBANE
CA
94005
0
1
0
0
Sr. VP & Chief Comm. Officer
Common Stock
2017-11-20
4
F
0
3358
13.17
D
263866
D
Common Stock
2017-11-21
4
S
0
5215
13.2589
D
258651
D
The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity grants.
This sale was effected for tax planning purposes pursuant to the Reporting Person's Rule 10b5-1 Trading Plan dated September 20, 2017.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.21 to $13.395, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
George Abercrombie
2017-11-22